首页> 外文OA文献 >PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS: A SYSTEMATIC REVIEW

【2h】

PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS: A SYSTEMATIC REVIEW

机译：PMU4 - 在参考生物制药和生物纤维单体之间切换的安全性：系统评价

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
L Barbier; H Ebbers; S Simoens; P Declerck; A Vulto; I Huys;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab [J] . Feagan Brian G., Lam Gordon, Ma Christopher, Alimentary pharmacology & therapeutics. . 2019,第1期

机译：系统评价：参考和生物仿生素之间的切换患者的疗效和安全性
2. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes [J] . Cohen Hillel P., Blauvelt Andrew, Rifkin Robert M., Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts . 2018,第4期

机译：切换参考药物到生物纤米：临床结果的系统文献综述
3. Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes'' [J] . Cohen Hillel P., Blauvelt Andrew, Rifkin Robert M., Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts . 2018,第8期

机译：作者对Pires等人的回复：“切换参考药物到生物仿制物：临床结果的系统文献综述”
4. Comprehensive structural characterization of biopharmaceuticals by top-down mass spectrometry and hydrogen/deuterium exchange: implication for biosimilars [C] . Jingxi Pan, Derek Smith, Christoph H. Borchers ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：自上而下的质谱和氢气/氘交换的生物药物综合结构表征：生物仿制性的含义
5. Facilitators and Barriers to Biosimilar Adoption: a Systematic Review of the Global Stakeholder Perspective [D] . Nair, Sonam. 2020

机译：促进者和生物仿制剂的障碍：对全球利益攸关方认为的系统审查
6. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab [O] . Brian G. Feagan, Gordon Lam, Christopher Ma, -1

机译：系统评价：在参考药物和生物仿制药英夫利昔单抗之间切换患者的疗效和安全性
7. Efficacy and Safety of Biosimilar Insulins Compared to Their Reference Products: A Systematic Review [O] . C Tieu, M DePaola, E Lucas, 2018

机译：生物仿生胰岛素的功效和安全与他们的参考产品相比：系统审查

PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS: A SYSTEMATIC REVIEW

著录项

引文网络

相似文献

相关主题

期刊订阅